Neurology Enrollment: Why sites miss dates even if willing patients are willing to enroll

Here’s what recruitment has to get right so willing patients reach a trial ready to enroll them.

Every September, World Alzheimer's Day asks the world to remember the people behind a diagnosis and the families beside them.

This year, the 2026 World Alzheimer Report puts clinical trials at the center of that conversation (Alzheimer's Disease International, 2026).

For families living with dementia and Parkinson's disease, that recognition matters. The research they are counting on is named out loud, in front of everyone.

In neurology, willingness is seldom the problem. Before sites opened on a recent Parkinson's protocol, we tested its eligibility rules against 214 real patients. 9 qualified. What kept that number low was the protocol's device-history requirement, not a shortage of people ready to take part (Antidote/83bar, 2026, n=214).

Precision recruitment counts the right conversations,
not impressions 

Precision patient recruitment matches a specific protocol to the specific patients who fit it, then guides those patients to a clinical research site ready to enroll. Broad outreach counts impressions. Precision recruitment counts the right conversations.

For a neurology trial, that means finding the people whose diagnosis, stage, and history match the protocol, then keeping them engaged until a site can take them.

Neurology trials stall between the click and the
clinical research site 

Neurology trials seldom stall for lack of interest. They stall because the right patients get lost between a click and a clinical research site. Four patterns show up again and again:

• Broad outreach floods screening with people who do not fit the protocol.
• Willing patients wait days for contact, and hope cools.
• Handoffs reach coordinators without the detail they need.
• The patients who fit best are the hardest to find in the noise.
  
  

Broad outreach and precision recruitment pull in opposite directions:

What hundreds of studies have taught us about enrolling neurology trials

Here is what we have learned across hundreds of clinical studies: the trials that enroll on time are not the ones that reach the most people. They are the ones where the patient who arrives at a clinical research site is ready to enroll, not ready to be screened from the start again. Four things separate a program that enrolls on time from one that stalls:

1. Outreach matched to the real protocol, so the message reaches the people who fit.
2. Patient education, so a willing person understands what taking part involves.
3. A clinical contact center that speaks with real people before a clinical research site does.
4. A clean, site-ready handoff, so coordinators enroll instead of re-screening.

A site-ready patient is one a coordinator can enroll
on the first visit

A site-ready patient is one a coordinator can enroll on the first visit, without starting the screening over. 

Before the handoff, the strongest programs have already confirmed the diagnosis and stage match the protocol, checked the key eligibility criteria in a real conversation, and made sure the patient understands the commitment and wants to continue, with travel, schedule, and consent questions answered. 

That is the difference between a referral a site has to work through and a patient a site can enroll.

Behind every number in a neurology trial is a person holding on to hope.

Recruitment's job is to help that hope find the right door.

This World Alzheimer's Day, as the world puts clinical trials at the center, that is a job worth doing right.